22nd Century Group

22nd Century Group, Inc. (Nasdaq: XXII) is a pioneering plant biotechnology company dedicated to enhancing human health through advanced plant science. The company specializes in tobacco harm reduction by developing reduced nicotine content (RNC) tobacco plants and cigarettes. Utilizing proprietary, patent-protected intellectual property to control nicotine biosynthesis in tobacco plants, 22nd Century Group has introduced the first market-ready cigarettes containing 95% less nicotine. These products are designed to help smokers reduce their cigarette consumption, and the company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021.

22nd Century Group operates primarily in the life sciences and consumer products industries, creating new, proprietary plants with specific alkaloid profiles, improved yields, and valuable agronomic traits. The company serves a diverse range of clients, including those in the tobacco industry, life sciences, and consumer products sectors. Its business model revolves around leveraging its innovative plant biotechnology to develop and commercialize products that promote health and well-being.

Revenue is generated through the sale of its reduced nicotine content cigarettes, licensing of its proprietary technology, and partnerships with other companies in the life sciences and consumer products industries. The company's mission is ambitious: to sell the last combustible tobacco cigarette before the start of the 22nd Century.

Keywords: plant biotechnology, tobacco harm reduction, reduced nicotine, FDA authorization, nicotine biosynthesis, proprietary plants, life sciences, consumer products, health enhancement, innovative technology.